[Survival and relapses assessment in patients with Wegener's granulomatosis and predominant renal involvement].
BACKGROUND
Wegener's granulomatosis (WG) is a potentially fatal condition with remissions and high relapses rates.


OBJECTIVE
Assessment of survival and relapses in a population based cohort of patients with WG with predominant renal involvement.


METHODS
A prospective cohort study including 60 patients--median age of 42 years with different dynamics and clinical presentation. Patients were divided into 3 groups (group 1, group 2 and group 3 respectively, and subgroups: 3.1, 3.2, 3.3): group 1--WG patients without renal involvement, group 2--WG patients with abnormalities in urinary sediment, group 3.1--WG patients with chronic renal failure, group 3.2--WG patients with diffuse alveloar hemorrhage (DAH) and rapid progressive glomerulonephritis (RPGN), and group 3.3--WG patients with RPGN. The clinical analysis has been conducted using the disease extent index (DEl) only and Birmingham Vasculitis Activity Score-Wegener's granulomatosis (BVAS-WG) disease activity questionnaire. Logistic regression analysis and the Wilcoxon test were used. Survival time and death risk were assessed using the Kaplan-Meier estimator and Cox proportional hazard model.


RESULTS
Eighty-eight percent of patients survived the first year follow-up since the diagnosis, while 84% of patients remained alive after the second year of observation. Life expectancy was 67.1 +/- 4.4 months. During the first year of observation 9.8% of patients died, after 2 years death hazard amounted to 3.7% per year, and after 4 years 2.6% per year (p < 0.05). Death risk was 1.3-fold higher in group 2 and 3.3-fold higher in group 3 compared to group 1 (p > 0.05). Mortality in patients from group 3.1 was 6-fold lower than in patients from group 3.2 (p < 0.03) and in group 3.3 was more than 4-fold lower than in patients from group 3.2 (p < 0.04). Relapse risk after first the year of follow-up was 20% per year and minimally changed after 3 years of observation, then decreased to 6% after 5 years. Relapse hazard ratio in group 2 was significantly lower in comparison with group 1 (HR1/3.6, p < 0.04).


CONCLUSIONS
We found significant differences in survival and relapses in various subpopulationsof WG patients.
Zycińska
Katarzyna
K
Poradnia Układowych Zapaleń Naczyń, Oddział Kliniczny Medycyny Rodzinnej, Chorób Wewnetrznych i Metabolicznych, Akademia Medyczna, Warszawa. kzycinska@poczta.fm
Wardyn
Kazimierz A
KA
D000293:Adolescent; D000328:Adult; D000368:Aged; D015897:Comorbidity; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000517:prevention & control*; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000517:prevention & control*; D006801:Humans; D053208:Kaplan-Meier Estimate; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome
D003520:Cyclophosphamide